Thermosensitive slow-release pharmaceutical composition of taxane drugs

A technology of taxanes and compositions, applied in the field of medicine, can solve the problems of patient suffering, dose-dependent immunosuppression, hypersensitivity reactions and the like

Active Publication Date: 2017-06-13
王子厚
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the structure, microtubule binding ability and pharmacokinetic characteristics of different taxane drugs are different, they have similar side effects, such as dose-dependent immunosuppression, followed by neurotoxicity, mucositis, and hair loss. and gastrointestinal reactions
And because the solubility of taxane drugs in water is low, non-ionic surfactants are often used for solubilization in the injections of such drugs on the market. For example, polyoxyethylated castor oil is used for solubilization in paclitaxel injection. However, docetaxel injection uses Tween 80 to solubilize, etc., and these solvents usually cause hypersensitivity reactions and bring great pain to patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thermosensitive slow-release pharmaceutical composition of taxane drugs
  • Thermosensitive slow-release pharmaceutical composition of taxane drugs
  • Thermosensitive slow-release pharmaceutical composition of taxane drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Embodiment 1: preparation pharmaceutical composition of the present invention

[0089] formula

[0090] paclitaxel 0.2g Chitosan 2g Sodium β-Glycerophosphate 10g ethanol 2.5g Cit 1 / 100 water Appropriate amount, add to 100g Final solution pH 7.0

[0091] Preparation: under the conditions of preparing sterile preparations, prepare according to the following steps:

[0092] a) dissolving chitosan with an aqueous solution (0.1M acetic acid) of an acidic reagent is made into a 2.5% chitosan solution;

[0093] b) dissolving taxanes in ethanol, then slowly adding it to the above-mentioned chitosan solution, autoclaving, cooling in an ice-water bath for at least 30 minutes, and setting aside;

[0094] c) Dissolve β-glycerophosphate sodium in an appropriate amount of water for injection to make a solution with a concentration of 60%, pass through a 0.22 μm filter membrane to sterilize, cool in an ice-water bath for at least...

Embodiment 2

[0097] Embodiment 2: preparation pharmaceutical composition of the present invention

[0098] formula:

[0099] paclitaxel 0.05g Chitosan 3g Sodium β-Glycerophosphate 5g ethanol 5g Cit 0.5 / 100 water Appropriate amount, add to 100g Final solution pH 6.5

[0100] Preparation: According to the method of Example 1, in step a), 0.1M hydrochloric acid is used to dissolve chitosan.

[0101] The results of the fluidity assay: gelation time (t1, 37°C)=7min, decoagulation time (t2, 20°C)=56min.

Embodiment 3

[0102] Embodiment 3: preparation pharmaceutical composition of the present invention

[0103] formula:

[0104] paclitaxel 0.5g Chitosan 1g Sodium β-Glycerophosphate 15g ethanol 1g Cit 2 / 100 water Appropriate amount, add to 100g Final solution pH 7.5

[0105] Preparation: Carry out with reference to the method of Example 1.

[0106] The measurement results of the fluidity assay method: gelation time (t1, 37°C)=57min, decoagulation time (t2, 20°C)=12min.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
cumulative release rateaaaaaaaaaa
Login to view more

Abstract

The invention relates to a temperature-sensitive controlled-release pharmaceutical composition of taxane drugs. Specifically speaking, the invention relates to the pharmaceutical composition which comprises taxane drugs, chitosan, sodium beta-glycerophosphate, ethanol and water, and further relates to a preparation method for the pharmaceutical composition. The pharmaceutical composition can be used for preparation of anticancer drugs. In particular, the anticancer drugs are applied to treatment of malignant tumors or prevention of recurrence after operation through a stereotaxical injection approach and can be cooperatively used with radiotherapy and traditional Chinese medicine.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a pharmaceutical composition for tumor / cancer treatment, in particular to a slow-release temperature-sensitive pharmaceutical composition containing taxane pharmaceutical components. The composition of the present invention can be administered by intratumoral injection, peritumoral injection and other localized injection methods for the treatment of various tumors, especially for those tumors that are highly toxic or cannot be treated with conventional chemotherapy or radiation, it can be administered after localization. Local injection in the tumor can increase the drug concentration to improve the curative effect and reduce systemic toxicity. Background technique [0002] Cancer is a disease caused by abnormalities in the mechanisms that control cell growth and proliferation. In addition to being able to proliferate indefinitely, cancer cells can locally invade surrounding no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/08A61K9/06A61K31/337A61K47/36A61K47/24A61K47/12A61P35/00
Inventor 陈西敬王子厚李萃云李大魁唐伟松曲昌海冯凤仪赵娣梅丹
Owner 王子厚
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap